Parenteral iron preparations, like Ferric carboxymaltose (FCM), are commonly used to manage moderate-to-severe iron deficiency anemia.1 FCM is a novel intravenous iron formulation offering rapid correction of iron deficiency anemia and effective iron store replenishment, making it valuable for cancer patients. It delivers up to 1000?mg iron in a single, 15?minute dose, facilitating swift hemoglobin recovery and improving patient outcomes. FCM demonstrates safety and tolerance comparable to traditional treatments, with fewer gastrointestinal side effects than oral iron. Its controlled-release mechanism reduces free iron-related toxicity. For oncology and hematology patients who often exhibit treatment-related anemia, FCM provides a convenient, efficient, and well-tolerated therapeutic option.